Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Hits New 52-Week High – What’s Next?

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) hit a new 52-week high during mid-day trading on Tuesday . The stock traded as high as $68.99 and last traded at $72.8550, with a volume of 13010 shares changing hands. The stock had previously closed at $63.53.

Analyst Ratings Changes

Several analysts have recently commented on KNSA shares. Citigroup increased their price objective on Kiniksa Pharmaceuticals International from $50.00 to $60.00 and gave the company a “buy” rating in a report on Wednesday, April 29th. Wells Fargo & Company upped their price objective on shares of Kiniksa Pharmaceuticals International from $57.00 to $74.00 and gave the company an “overweight” rating in a report on Monday, July 13th. Jefferies Financial Group increased their price objective on shares of Kiniksa Pharmaceuticals International from $58.00 to $71.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Wedbush boosted their target price on shares of Kiniksa Pharmaceuticals International from $59.00 to $72.00 and gave the stock an “outperform” rating in a research report on Monday, June 29th. Finally, The Goldman Sachs Group upped their price target on shares of Kiniksa Pharmaceuticals International from $60.00 to $75.00 and gave the company a “buy” rating in a research note on Thursday, July 23rd. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Hold rating to the company. According to data from MarketBeat, Kiniksa Pharmaceuticals International currently has a consensus rating of “Buy” and an average target price of $68.00.

Kiniksa Pharmaceuticals International Stock Up 21.3%

The stock has a 50-day moving average of $57.07 and a 200 day moving average of $50.18. The stock has a market cap of $5.93 billion, a PE ratio of 84.46 and a beta of 0.07.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its quarterly earnings data on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, meeting the consensus estimate of $0.30. The business had revenue of $243.60 million during the quarter, compared to analysts’ expectations of $226.49 million. Kiniksa Pharmaceuticals International had a net margin of 9.69% and a return on equity of 13.26%. On average, equities analysts anticipate that Kiniksa Pharmaceuticals International, plc will post 1.25 EPS for the current year.

Insider Activity

In other news, CEO Sanj K. Patel sold 48,565 shares of the firm’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $54.02, for a total transaction of $2,623,481.30. Following the sale, the chief executive officer owned 48,565 shares of the company’s stock, valued at $2,623,481.30. This trade represents a 50.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider John F. Paolini sold 58,424 shares of the stock in a transaction on Friday, May 1st. The stock was sold at an average price of $53.71, for a total transaction of $3,137,953.04. Following the sale, the insider directly owned 65,623 shares in the company, valued at $3,524,611.33. This trade represents a 47.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 131,674 shares of company stock worth $7,094,671. 51.98% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Kiniksa Pharmaceuticals International

A number of institutional investors have recently modified their holdings of KNSA. Rubric Capital Management LP raised its holdings in Kiniksa Pharmaceuticals International by 2.3% in the 3rd quarter. Rubric Capital Management LP now owns 4,000,000 shares of the company’s stock worth $155,320,000 after purchasing an additional 90,194 shares during the period. Vanguard Group Inc. raised its stake in shares of Kiniksa Pharmaceuticals International by 1.6% during the 4th quarter. Vanguard Group Inc. now owns 3,112,937 shares of the company’s stock worth $128,409,000 after buying an additional 49,802 shares during the period. Arrowstreet Capital Limited Partnership raised its stake in shares of Kiniksa Pharmaceuticals International by 45.3% during the 3rd quarter. Arrowstreet Capital Limited Partnership now owns 1,068,263 shares of the company’s stock worth $41,481,000 after buying an additional 332,846 shares during the period. Qube Research & Technologies Ltd lifted its position in shares of Kiniksa Pharmaceuticals International by 277.8% during the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares in the last quarter. Finally, Millennium Management LLC lifted its position in shares of Kiniksa Pharmaceuticals International by 8.7% during the 1st quarter. Millennium Management LLC now owns 847,124 shares of the company’s stock valued at $18,815,000 after buying an additional 67,452 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International, Inc is a biopharmaceutical company focused on discovering, acquiring and developing therapeutics for patients suffering from lifethreatening and debilitating immune-mediated diseases. Founded in 2013 and headquartered in Lexington, Massachusetts, Kiniksa applies a patient-centric approach to build a diversified portfolio of marketed medicines and clinical-stage candidates targeting inflammation and immunology. The company’s core mission is to address complex conditions with significant unmet medical needs by advancing both novel and differentiated therapies.

The company’s lead marketed product is Ilaris (canakinumab), an interleukin-1? blocker licensed for the treatment of cryopyrin-associated periodic syndromes, systemic juvenile idiopathic arthritis, adult-onset Still’s disease and Schnitzler syndrome.